G1 Therapeutics Inc
NASDAQ:GTHX
Balance Sheet
Balance Sheet Decomposition
G1 Therapeutics Inc
G1 Therapeutics Inc
Balance Sheet
G1 Therapeutics Inc
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
4
|
23
|
47
|
104
|
369
|
269
|
207
|
221
|
95
|
32
|
|
| Cash Equivalents |
4
|
23
|
47
|
104
|
369
|
269
|
207
|
221
|
95
|
32
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
51
|
50
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
11
|
13
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
11
|
13
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
16
|
12
|
|
| Other Current Assets |
0
|
1
|
1
|
1
|
1
|
2
|
9
|
13
|
7
|
8
|
|
| Total Current Assets |
4
|
24
|
48
|
105
|
370
|
271
|
216
|
244
|
180
|
115
|
|
| PP&E Net |
0
|
0
|
0
|
1
|
1
|
13
|
11
|
9
|
8
|
6
|
|
| PP&E Gross |
0
|
0
|
0
|
1
|
1
|
13
|
11
|
9
|
8
|
6
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
0
|
|
| Total Assets |
4
N/A
|
24
+529%
|
48
+102%
|
105
+118%
|
371
+253%
|
285
-23%
|
229
-20%
|
254
+11%
|
188
-26%
|
122
-35%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
1
|
3
|
4
|
3
|
4
|
4
|
3
|
7
|
4
|
|
| Accrued Liabilities |
0
|
1
|
3
|
8
|
9
|
16
|
18
|
24
|
27
|
23
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
2
|
3
|
|
| Total Current Liabilities |
0
|
2
|
6
|
12
|
12
|
20
|
23
|
28
|
36
|
30
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
20
|
75
|
77
|
52
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
10
|
8
|
8
|
7
|
5
|
|
| Total Liabilities |
0
N/A
|
2
+633%
|
6
+155%
|
12
+111%
|
13
+6%
|
29
+134%
|
51
+75%
|
111
+116%
|
119
+8%
|
86
-28%
|
|
| Equity | |||||||||||
| Common Stock |
14
|
53
|
108
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
11
|
32
|
65
|
129
|
214
|
337
|
436
|
585
|
732
|
780
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
223
|
573
|
592
|
614
|
728
|
801
|
815
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
4
N/A
|
22
+520%
|
43
+96%
|
93
+119%
|
359
+284%
|
256
-29%
|
177
-31%
|
144
-19%
|
69
-52%
|
35
-48%
|
|
| Total Liabilities & Equity |
4
N/A
|
24
+529%
|
48
+102%
|
105
+118%
|
371
+253%
|
285
-23%
|
229
-20%
|
254
+11%
|
188
-26%
|
122
-35%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
27
|
27
|
27
|
28
|
37
|
38
|
38
|
43
|
52
|
52
|
|